Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study

JTO Clinical and Research Reports(2023)10.1016/j.jtocrr.2023.100592Source: DataRank Database

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study is a research paper published in JTO Clinical and Research Reports (2023). On theSindex it has a DataRank of 0.312. It has been cited 7 times.

N/A

0.312DataRank · unranked

Scored on demand from live citation data

Open Access7 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 1.14)OA: goldTopics (24)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.312

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (9)

Renjian Jiang ORCID,Zhonglu Huang,Becky Bunn,Murry W. Wynes,Jeffrey M. Switchenko ORCID

Live enrichment

PubMed:38827378 PMC:PMC11143895 OpenAlex:https://openalex.org/W4387783276

National Cancer Institute

Grant: P30CA138292

National Cancer Institute

Grant: P50CA217691

National Institutes of Health

International Association for the Study of Lung Cancer

Winship Cancer Institute

FWCI

1.14

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.jtocrr.org/article/S2666-3643(23)00135-2/pdf

publisherhttps://www.jtocrr.org/article/S2666-3643(23)00135-2/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666364323001352?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364323001352?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtocrr.2023.100592

Fields of Study

Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Keywords

Lung cancerMedicineExonOncologyInternal medicineAdenocarcinomaMutationEpidermal growth factor receptorTyrosine kinaseLungTyrosine-kinase inhibitorCancer researchCancerGeneBiologyGeneticsReceptorNSCLCCancerlinqEgfr Exon20Real-World Data Iaslc

Natural History and Real-World Treatment Outcomes for Patients With NSCLC Having EGFR Exon 20 Insertion Mutation: An International Association for the Study of Lung Cancer–American Society of Clinical Oncology CancerLinQ Study

FAIR Checklist

DataRank Breakdown

Authors (9)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)